LEADER One Year On

Topics for Discussion

LEADER: Study Design

LEADER: Primary Outcome Measure*

LEADER: Death From CV Causes

LEADER: HHF

LEADER: Time to First Renal Event*

LEADER: Primary Outcome Subgroup Analyses

LEADER: Study Population Baseline CV Risk Profile

LEADER: Overall Summary of AEs

LEADER: Selected AEs of Special Interest

Completed CVOTs in T2DM

SUSTAIN 6: Study Design

SUSTAIN-6: Primary Outcome Measure*

SUSTAIN-6: CV Endpoints

ELIXA: Primary Outcome Measure*

GLP-1 RAs: Overview of Clinical Characteristics and Pharmacokinetics

ELIXA, LEADER, and SUSTAIN-6: Similarities and Differences

CV Outcomes for DPP-4 Inhibitors

SAVOR-TIMI 53, EXAMINE, and TECOS: HHF

DPP-4 Inhibitors and HF Risk

EMPA-REG OUTCOME: Trial Design

EMPA-REG OUTCOME: Primary Outcome Measure*

EMPA-REG OUTCOME: HHF

Similarities and Differences of Patient Characteristics in EMPA-REG OUTCOME and LEADER

EMPA-REG OUTCOME: CV Death, MI, and Stroke

Cross-Trial Comparisons

EMPA-REG OUTCOME Microvascular Outcomes: Renal Protection

GLP-1 RAs: Is There a Relationship Between Half-Life and Clinical Outcomes?

Potential Mechanisms of SGLT2 Inhibitors Resulting in CV Outcomes

EXSCEL: Top-Line Results

Available Evidence From CVOTs and Patients With T2DM

SGLT2 Inhibitors and Lower-Limb Amputations

Candidates for Antihyperglycemic Therapy With Effects on CV Outcomes: Empagliflozin, Liraglutide, Semaglutide

2017 ADA Standards of Medical Care in Diabetes

Should SGLT2 Inhibitors and GLP-1 RAs Be Combined to Provide Extreme CV Benefits?

Summary and Conclusions

Summary and Conclusions (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)